Argenx price target raised to $620 from $553 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Argenx (ARGX) to $620 from $553 and keeps an Overweight rating on the shares following “another strong showing” for Vyvgart in Q3. The firm told investors that Q3 results underscore Argenx’s “growing dominance” in the neuromuscular space, which it expects will be durable. Piper added that the firm remains a buyer of the stock. Argenx has set an “extremely high bar” with Vyvgart’s clinical profile and has solidified themselves as “dominant players” in the generalized myasthenia gravis space, according to the firm.